The efficacy of tolvaptan for patients with chronic kidney disease and chronic heart failure

The efficacy of tolvaptan for patients with chronic kidney disease and chronic heart failure - The efficacy of tolvaptan in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031781

Enrollment

Registered

2018-03-18

Start date

2018-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients (stage3, stage4, stage5) who were prescribed tolvaptan

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Urine volume, body weight, blood pressure Physical assessment L/D (Na, K, Cl, osmolarity, BUN,Cr, ADH, urine electrolytes, L-FABP, NAG)	—

Countries

Japan

Contacts

Public ContactHiroki Kobayashi

Nihon University School of Medicine Division of Nephrology, Hypertension, and Endocrinology

kobayashi.hiroki@nihon-u.ac.jp03-3972-8111

Outcome results